This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

warfarin and tramadol

Authoring team

Taking warfarin and tramadol together can cause harmful drug interactions, which can raise the International Normalised Ratio (INR), and result in severe bruising and bleeding, which in some patients could be fatal.

Advice for healthcare professionals:

  • warfarin is a coumarin-derived vitamin K antagonist which has a low therapeutic index, so continue to exercise caution when co-prescribing warfarin with other drugs, to minimise the risk of drug interactions
  • ask patients about all the medicines that they are currently taking
  • be aware of the risk of increased INR when warfarin and tramadol are used together, with a risk of major bruising and bleeding which could be life-threatening
  • consult the product information of any new concomitant therapy for specific guidance on use with warfarin and consider whether warfarin dose adjustment is required
  • consider whether additional monitoring of INR is required when starting tramadol or another concomitant medicine
  • ensure patients are aware of the need to seek medical treatment should they notice the signs of a major bleeding event
  • caution should also be taken if tramadol is co-prescribed with other coumarin-derived anticoagulants such as acenocoumarol
  • report suspected adverse drug reactions to the Yellow Card scheme

Reference:

  • Drug Safety Update volume 17, issue 11: June 2024: 2

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.